Based on this YouTube video's total view count of 166K views and industry-standard rates, the estimated total earning is $117 - $333 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Vaccine reduces spread with 166,543 views, 6,632 likes, and 2,251 comments. Experience the impact of this video content that has captured audience attention.

Oxford vaccine https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268 Background Approved for emergency use by MHRA Two standard doses, 4 to 12 weeks Pooled analysis of trials Exploratory analyses, immunogenicity and efficacy of extended intervals Priming and booster doses Data after one dose Methods Phase III efficacy trials in the United Kingdom and Brazil Phase I/II clinical trials in the UK and South Africa Data cut-off, 7th December 2020 Over 18 years, randomised 1:1 Blinded independent endpoint review committee Participants N = 17,177 baseline seronegative participants UK, n = 8,948 Brazil, n = 6,753 South Africa, n = 1,476 Infections after first dose Positive infections, n = 619 Symptomatic infections, less than 14 days after dose, n = 332 (up by 201 from 131) Primary analysis of overall vaccine efficacy Including LD/SD and SD/SD groups, = 66.7% (57.4%, 74.0%) Vaccine group Hospitalisations = 0 Control group Hospitalisations = 15 Hospitalisations after a single dose Less than 22 days 2 in vaccination group, 7 in control group More than 22 after first dose 0 in the vaccination group, 6 in the control group Vaccine efficacy after a single standard dose From day 22 to day 90 = 76% Protection did not wane during this initial 3-month period Antibody levels were maintained during this 90-day period Minimal waning by day 90 Efficacy with a longer prime-boost interval VE = 82.4% at 12+ weeks Efficacy with less than 6 week, prime-boost interval VE = 54.9% Observations supported by immunogenicity data Binding antibody responses more than 2-fold higher after an interval of 12 weeks or more Compared with and interval of less than 6 weeks (18-55 years) Interpretation UK single dose strategy, booster at 3 months is an effective strategy for reducing disease, and may be the optimal for rollout of a pandemic vaccine when supplies are limited in the short term It is the dosing interval and not the dosing level which has a great impact on the efficacy of the vaccine Longer prime-boost intervals done with other vaccines such as influenza, Ebola and malaria. Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA and EMA to grant the vaccine emergency use authorisation It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation (JCVI) for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected from 22 days after a single dose of the vaccine Vaccinated people less contagious Analyses of PCR positive swabs in UK Vaccine may have substantial reducing effect on transmission of the virus 67% reduction in positive swabs among those vaccinated

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.